Prevalence of Erectile Dysfunction in Dyslipemic Patients.

Prevalence of Erectile Dysfunction in Dyslipemic Patients, S. F. Sanchez, Centro de Salud de Rotgla, Spain; V. J. Aznar, SICC-APM, Spain; C. Llisterri, CS Ingeniero Joaquin Benlloch, Spain; F. Garcia, CS Mislata, Spain; F. R. Solbes, CS Republica Argentina, Spain; V. R. Albelda, CS Xativa, Spain; G. Lafuente, CS Llosa de Ranes, Spain; R. T. Sanchez, CS Benasal, Spain

We studied the prevalence of erectile dysfunction (ED) and its correlation with other factors of cardiovascular risk in dyslipemic patients attended by 30 family doctors in the Valencian community in a cross-sectional and multicentric descriptive study in patients men of 40 to 65 years diagnosed of dyslipemia (serum cholesterol > 200 mg/dl and/or cholesterol LDL > 130 mg/dl and/or cholesterol HCL < 40 mg/dl) and not using hypolipemiants drugs, who were selected by consecutive sampling. The patients with treatments or pathologies of recognized influence on the sexual function excluded themselves, as did those with arterial hypertension (HTA; blood pressure [greater than or equal to]140 and/or 90 mm Hg). ED it was diagnosed at the beginning of the study by the IIEE We found that 161 men included themselves, with an average age of 54 years, BMI of 27 Kg/[m.sup.2], and with dyslipemia for an average of 3 years. 35% of the patients used antihypertensive drugs. 36% were smokers, 19% were obese, and 71% were habitual drinkers. The prevalence of ED was 43%. Significant findings included (a) age: the increase of the age by one year increased the probability of suffering from ED by 1.135 times; and (b) serum creatinine: the increase of 0.1 mg/dl increased the probability of ED by 1.762 times. ED was not related to obesity, length of HTA or dyslipemia, or tobacco use. The values of total serum cholesterol, cLDL, and cHDL were not significantly different between both groups from dyslipemic patients (with or without ED).